+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

In vitro susceptibilities of clinical isolates of coagulase-negative staphylococci to glycopeptide antibiotics



In vitro susceptibilities of clinical isolates of coagulase-negative staphylococci to glycopeptide antibiotics



Japanese Journal of Antibiotics 51(12): 735-745



Two hundred and thirteen clinical strains of coagulase-negative staphylococci isolated in Japan between 1980 and 1997 were analyzed for glycopeptide susceptibility by determining MIC using both Mueller-Hinton agar (MHA) and Brain Heart Infusion agar (BHIA) plates. Of 37 Staphylococcus epidermidis strains isolated between 1980 and 1981, all were susceptible to vancomycin and teicoplanin on both MHA and BHIA. However, of 122 isolates of Staphylococcus epidermidis isolated between 1994 and 1997, 1 (0.8%) was intermediate to vancomycin on MHA and 39 (32%) were intermediate on BHIA, while 3 (2.5%) and 27 (22.1%) were intermediate or resistant to teicoplanin on MHA and BHIA, respectively. It was demonstrated that the susceptibilities of the strains in 1990s to vancomycin and teicoplanin were significantly decreased compared with those in 1980s. Population analysis was performed with six strains each of Staphylococcus epidermidis and Staphylococcus haemolyticus (three with vancomycin MIC > or = 8 micrograms/ml and three with vancomycin MIC < or = 4 micrograms/ml using BHIA). The population curves of the Staphylococcus epidermidis strains showed a homogeneous pattern of susceptibility. Whereas, those for two Staphylococcus haemolyticus strains (vancomycin MIC = 8 micrograms/ml using BHIA) showed a typical heterogeneous pattern. Vancomycin-resistant mutants (MIC > or = 32 micrograms/ml) were obtained with a high frequency of 10(-4)-(-5) from the strains by one-step selection with 16 micrograms/ml of vancomycin.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 046364054

Download citation: RISBibTeXText

PMID: 10077772


Related references

Reduced susceptibilities to glycopeptides among clinical isolates of coagulase-negative staphylococci. Abstracts of the General Meeting of the American Society for Microbiology 100: 208, 2000

Decreased Susceptibilities to Teicoplanin and Vancomycin among Coagulase-Negative Methicillin-Resistant Clinical Isolates of Staphylococci. Antimicrobial Agents and Chemotherapy 42(1): 100-107, 1998

Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci. Antimicrobial Agents and ChemoTherapy 42(1): 100-107, 1998

Relationship between glycopeptide use and decreased susceptibility to teicoplanin in isolates of coagulase-negative staphylococci. European Journal of Clinical Microbiology and Infectious Diseases 23(5): 375-379, 2004

Decreased susceptibility to glycopeptide antibiotics among coagulase-negative staphylococci from blood cultures. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 38: 144, 1998

Comparative activity of glycopeptide antibiotics against coagulase-negative staphylococci embedded in fibrin clots. Journal of Antimicrobial ChemoTherapy 30(3): 321-326, 1992

Susceptibilities of coagulase negative staphylococci to aminoglycosides antibiotics as compared by early bactericidal assays. Annales de Biologie Clinique 48(8): 541-546, 1990

In vitro susceptibilities of four species of coagulase-negative staphylococci. Antimicrobial Agents and ChemoTherapy 30(4): 545-552, 1986

In vitro antimicrobial susceptibilities of oxacillin-resistant coagulase negative staphylococci. Methods and Findings in Experimental and Clinical Pharmacology 7(6): 333-335, 1985

Selection of glycopeptide resistant coagulase-negative staphylococci in an in-vitro pharmacokinetic model. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 37: 74, 1997

In-vitro evaluation of quinupristin/dalfopristin and linezolid against clinical isolates of coagulase-negative staphylococci recovered from sterile body sites. International Journal of Antimicrobial Agents 17(Suppl. 1): S126, 2001

Species identification and antibiotic susceptibilities of coagulase-negative staphylococci isolated from clinical specimens. Journal of Clinical Microbiology 18(6): 1314-1319, 1983

Glycopeptide resistance among coagulase-negative staphylococci that cause bacteremia: epidemiological and clinical findings from a case-control study. Clinical Infectious Diseases 33(10): 1628-1635, 2001

In vitro activity of tea-tree oil against clinical skin isolates of meticillin-resistant and -sensitive Staphylococcus aureus and coagulase-negative staphylococci growing planktonically and as biofilms. Journal of Medical Microbiology 55(Pt 10): 1375-1380, 2006

In vitro activity of glycopeptide on one hundred fourteen coagulase-negative staphylococci: Problems with the the teicoplanin disk diffusion test alert parameters indicating a need for MIC determination. Pathologie Biologie 41(6): 531-536, 1993